


ESC Congress Munich 2018

25-29 August

Where the world of
cardiology comes together

**Final
Programme**



www.escardio.org/ESC2018
#ESCCongress



ESC

European Society
of Cardiology

11:00–12:30 | Brahms - The Hub

Ask a Question

CLINICAL TRIAL UPDATES

Late-Breaking Science

Chairpersons: M. Komajda (Paris, FR); D. Hasdai (Petah Tikva, IL)

11:00	COMPASS Trial - Bleeding and cancer risk in patients with vascular disease treated with Rivaroxaban.	1321
	- J.W. Eikelboom (Hamilton, CA)	
11:10	Discussant review - COMPASS.	1322
	- L. Wallentin (Uppsala, SE)	
11:15	CANTOS - Modulation of the Interleukin-6 Signaling Pathway and Incidence Rates of Atherosclerotic Events and Mortality.	1323
	- P.M. Ridker (Boston, US)	
11:25	Discussant review - CANTOS.	1324
	- M. Packer (Dallas, US)	
11:30	CABANA Trial - Recurrence of Atrial Arrhythmias in the Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation.	1325
	- J. Poole (Seattle, US)	
11:40	Discussant review - CABANA.	1326
	- C. Leclercq (Rennes, FR)	
11:45	ASCOT Legacy study - Longterm impact of the of BP and Lipid lowering treatment in hypertensive patients.	1327
	- A.K. Gupta (London, UK)	
11:55	Discussant review - ASCOT.	1328
	- To be announced	
12:00	ASCT-1 - 15-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis: extended post-trial follow-up of patients in the first Asymptomatic Carotid Surgery Trial.	1329
	- R. Bulbulia (Oxford, UK)	
12:10	Discussant review - ACST-1.	1330
	- M. Roffi (Geneva, CH)	
12:15	TRICS III - Restrictive versus liberal red blood cell transfusion in cardiac surgery: 6 month data.	1331
	- C.D. Mazer (Toronto, CA)	
12:25	Discussant review - TRICS-III.	1332
	- M. Sousa Uva (Lisbon, PT)	

11:00–12:30 | Haendel - The Hub

General Cardiology for Physicians, Technicians and General Practitioners

Ask a Question

SPECIAL ISSUES FROM THE 2017 ESC GUIDELINES ON VALVULAR HEART DISEASE IN GENERAL CARDIOLOGY

Symposium

Chairpersons: A. Haverich (Hannover, DE); L.A. Pierard (Liège, BE)

11:00	When TAVI and when surgery for severe aortic stenosis?	1333
	- J. Kovac (Leicester, UK)	
11:22	Functional and organic mitral regurgitation: not often a simple differentiation.	1334
	- A. Chinaglia (Turin, IT)	
11:45	Catheter interventions for valves besides TAVI: established, possible and future indications.	1335
	- T. Modine (Lille, FR)	
12:07	Don't forget the tricuspid valve.	1336
	- J.J. Gomez-Doblas (Málaga, ES)	

11:00–12:30 | Schumann - The Hub

Ask a Question

MEET THE EXPERTS – SAFETY FIRST: AVOIDING ADVERSE EVENTS WITH NEW CARDIOVASCULAR DRUGS

Expert Session

Meet the Experts Focused case discussions

Chairpersons: M.A. Alonso Garcia (London, UK); J.L. Tamargo (Madrid, ES)

11:00	Safety first: avoiding adverse events with new cardiovascular drugs - Panel.	1337
	- J.C. Kaski (London, UK), G.M.C. Rosano (London, UK), C. Ceconi (Desenzano del Garda, IT)	
11:00	Introduction - Safety first: avoiding adverse events with new cardiovascular drugs.	1338
	- M.A. Alonso Garcia (London, UK)	
11:05	Scenario 1 - Adverse events of new lipid lowering drugs.	1339
	- T.S. Hall (Oslo, NO)	
11:30	Scenario 2 - Nephilysin inhibitors in heart failure: safety and adverse events.	1340
	- M.I. Kaluzna-Oleksy (Poznan, PL)	
11:55	Scenario 3 - Long-term safety of new anti-diabetic drugs.	1341
	- A. Niessner (Vienna, AT)	
12:20	Safety first: avoiding adverse events with new cardiovascular drugs - Take Home Message.	1342
	- J.L. Tamargo (Madrid, ES)	

16:45–17:45 | Brahms - The Hub

Ask a Question

RADIATION EXPOSURE IN ELECTROPHYSIOLOGY AND CORONARY INTERVENTION: A CRITICAL APPRAISAL Symposium

Chairpersons: S. Ernst (London, UK); A. Sarkozy (Edegem, BE)

- 16:45 **Occupational radiation exposure in invasive cardiology.** 4269
– E. Picano (Pisa, IT)
- 17:05 **Is brain cancer an occupational disease of the cardiac interventionalist?** 4270
– A. Roguin (Haifa, IL)
- 17:25 **Strategies to reduce radiation exposure in electrophysiology and interventional cardiology.** 4271
– T.J.R. De Potter (Aalst, BE)

16:45–17:45 | Haendel - The Hub

Ask a Question

PULMONARY HYPERTENSION DUE TO LEFT HEART DISEASE: LOOK RIGHT! Symposium

Chairpersons: S. Rosenkranz (Cologne, DE); D. McGlothlin (San Francisco, US)

- 16:45 **Haemodynamic characterization of PH due to heart failure.** 4272
– S. Rosenkranz (Cologne, DE)
- 16:58 **The failing right heart in left heart diseases.** 4273
– M. Guazzi (San Donato Milanese, IT)
- 17:11 **Treatment of PH due to left heart diseases: hype, hope, facts and fiction.** 4274
– J.L. Vachiery (Brussels, BE)
- 17:24 **Pulmonary hypertension, RV dysfunction and major cardiac surgery: a tale of two hearts.** 4275
– R.J. Tedford (Charleston, US)
- 17:37 **Panel discussion.** 4276

16:45–17:45 | Schumann - The Hub

Ask a Question

ARE GENERIC DRUGS SAFE IN HEART FAILURE? Symposium

Chairpersons: T.A. Schmidt (Holbæk, DK); I. Savelieva (London, UK)

- 16:45 **Are regulations for generic CV drugs sufficient to guarantee their safety?** 4277
– J.L. Tamargo (Madrid, ES)
- 17:00 **Pharmacodynamic differences between generic and brand name drugs in heart failure.** 4278
– M. Lainscak (Murska Sobota, SI)
- 17:15 **Switching between brand name and generic drugs in heart failure. Is it safe?** 4279
– J.G.F. Cleland (Glasgow, UK)
- 17:30 **Panel discussion.** 4280


16:45–17:45 | Agora 1

CONTROVERSIES AND UNMET NEEDS AROUND TAVI Rapid Fire Abstracts

Chairpersons: M.S. Mourali (Tunis, TN); D. Pinto (Boston, US)

- 16:45 **Survival and Long-term clinical outcomes after Transcatheter Aortic Valve Replacement in high-risk patients with severe aortic stenosis.** 4281
– A.J. Munoz Garcia, E. Munoz-Garcia, M. Munoz-Garcia, A.J. Dominguez-Franco, F. Carrasco-Chinhilla, J.H. Alonso-Briales, J.J. Gomez-Doblas, M.F. Jimenez-Navarro, J.M. Hernandez-Garcia, E. De Teresa-Galvan (Málaga, ES)
- 16:55 **Tardive coronary obstruction after transcatheter aortic valve implantation. -- WITHDRAWN**
– R. Jabbour, A. Tanaka, A. Finkelstein, M. Mack, C. Tamburino, N. Van Mieghem, O. De Backer, L. Testa, V. Veulemans, J.M. Sinning, G. Tarantini, W. Scholtz, D. Tchetche, A. Colombo, A. Latib (London, UK; Tel Aviv, IL; Houston, US; Catania, San Donato Milanese, Padua and Milan, IT; Rotterdam, NL; Copenhagen, DK; Düsseldorf, Bonn and Bochum, DE; Toulouse, FR)
- 17:05 **Validation of the “multivalvular score” for the assessment of patients with concomitant mitral and aortic valve disease under evaluation for transcatheter aortic valve implantation.** 4282
– I.J. Amat Santos, P. Catala, A. Aparisi, C. Cortes, L.R. Goncalves Ramirez, H. Gutierrez Garcia, B. Ramos, A. Serrador, S. Vera, A. Revilla Orodea, I. Gomez, M. Carrasco Moraleja, J.A. San Roman Calvar (Valladolid, ES)
- 17:15 **Impact of primary hemostasis disorders on late (>30 days) major/life-threatening bleedings after TAVR.** 4283
– M. Kibler, B. Marchandot, N. Nathan, F. Vincent, L. Grunebaum, U. Crimzade, M. Kindo, M.T. Hoang, H. Petit-Eisenmann, L. Jesel, S. Susen, E. Van Belle, P. Ohlmann, O. Morel (Strasbourg and Lille, FR)
- 17:25 **Impact of coronary artery disease and PCI on Long-term outcomes of women undergoing transcatheter aortic valve replacement: insights from the multi-center WIN-TAVI registry.** 4284
– P. Guedeney, J. Chandrasekhar, A. Chieffo, J. Mehili, S. Sartori, G. Mikhail, T. Lefevre, U. Baber, S. Sorrentino, D. Tchetche, N.M. Van Mieghem, M.C. Morice, A.S. Petronio, R. Mehran (New York, US; Milan and Pisa, IT; Munich, DE; London, UK; Massy and Toulouse, FR; Rotterdam, NL)
- 17:35 **Impact of prosthetic valve regurgitation quantified by cardiac magnetic resonance imaging on long-term mortality after TAVI.** 4285
– M. Abdelghani, C. Merten, M. Landt, H.-W. Beurich, D. Zachow, G. Richardt, M. Abdel-Wahab (Bad Segeberg, DE)

14:30–15:45 | San Marino - Spotlight Village



ARRHYTHMOGENIC CARDIOMYOPATHY: FROM PATHOLOGY TO PROGNOSIS

Advances in Science

Chairpersons: P. Hlavak (Bratislava, SK); T. Wichter (Osnabrück, DE)

- 14:30 **Pathogenesis of ARVC - State of the art.** 5953
– E. Arbustini (Pavia, IT)
- 14:47 **Arrhythmic cardiomyopathy: a paradigm shift of the morphologic spectrum.** 5954
– M. De Gaspari, S. Rizzo, G. Thiene, C. Basso (Padua, IT)
- 15:01 **Anti-heart autoantibodies and arrhythmic cardiomyopathy: the role of inflammation in disease evolution.** 5955
– G. Halasz, F. Re, F. Regoli, M. Boscolo Berto, A. Caforio, M. Penco, M. Uguccioni, E. Zachara (Lugano, CH; Rome, Padua and L'Aquila, IT)
- 15:15 **Multimodality prediction of life-threatening ventricular arrhythmia in patients with arrhythmic cardiomyopathy; a prospective cohort study.** 5956
– O.H. Lie, C. Rootwelt, L.A. Dejgaard, I.S. Leren, M.K. Stokke, T. Edvardsen, K.H. Haugaa (Oslo, NO)
- 15:29 **Treatment of ARVC: current standards and future perspectives.** 5957
– T. Wichter (Osnabrück, DE)

14:30–15:45 | Bern - Village 1




EXPERT ADVICE – CHOLESTEROL-LOWERING TREATMENT MADE EASY

Expert Session

Chairpersons: T.R. Pedersen (Oslo, NO); V. Sansoy (Istanbul, TR)

- 14:30 **Cholesterol targets in secondary and primary prevention.** 5958
– U. Laufs (Homburg, DE)
- 14:48 **Statin treatment: which drug to choose and how to deal with side effects.** 5959
– S. Connolly (London, UK)
- 15:07 **When statins don't work: when and how to use other drugs.** 5960
– M. Sabatine (Boston, US)
- 15:26 **Panel discussion.** 5961

14:30–15:45 | Stockholm - Village 1




ANTITHROMBOTICS AND CANCER: CHALLENGES IN CLINICAL PRACTICE

Case-based Session

Chairpersons: V.L. Serebruany (West Friendship, US); J.L. Tamargo (Madrid, ES)

- 14:30 **Case 1 - A patient with AF and colon cancer.** 5962
– S. Garkina (St. Petersburg, RU)
- 14:55 **State of the Art lecture 1 - Cancer risk after dual antiplatelet therapy.** 5963
– M.H. Kim (Busan, KR)
- 15:20 **State of the Art lecture 2 - The link between hemostasis and cancer: what is clinically relevant?** 5964
– E. Hylek (Boston, US)

14:30–15:45 | Bratislava - Village 2



WHERE ARE WE WITH NEW TREATMENTS FOR HYPERTENSION?

Symposium

Chairpersons: A.J. McNeill (Londonderry, UK); M.S. Kucukoglu (Istanbul, TR)

- 14:30 **What is new in drug therapy for hypertension?** 5965
– R.K. Kreutz (Berlin, DE)
- 14:48 **An update on renal denervation.** 5966
– F. Mahfoud (Homburg, DE)
- 15:07 **Baroreceptor manipulation to treat hypertension.** 5967
– W. Spiering (Utrecht, NL)
- 15:26 **Panel discussion.** 5968